{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:28:11Z","timestamp":1791311291214,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clinthera.2015.02.003","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T01:47:53Z","timestamp":1425606473000},"page":"755-763","source":"Crossref","is-referenced-by-count":27,"title":["Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Elizabeth I.","family":"Buchbinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.02.003_bib1","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Accessed June 23, 2014. http:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"10.1016\/j.clinthera.2015.02.003_bib2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2015.02.003_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","article-title":"A new analysis of allogeneic interactions","volume":"53","author":"Lafferty","year":"1975","journal-title":"Aust J Exp Biol Med Sci"},{"key":"10.1016\/j.clinthera.2015.02.003_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.coi.2004.03.002","article-title":"Emerging paradigms of T-cell co-stimulation","volume":"16","author":"Kroczek","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib6","first-page":"116","article-title":"The B7-CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat?Rev Immunol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-065X.2008.00639.x","article-title":"CTLA-4: a key regulatory point in the control of autoimmune disease","volume":"223","author":"Scalapino","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2015.02.003_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib9","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4 mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J?Immunol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.0105-2896.2005.00249.x","article-title":"CTLA-4 gene polymorphism and autoimmunity","volume":"204","author":"Gough","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2015.02.003_bib11","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.4049\/jimmunol.151.7.3489","article-title":"Characterization of CTLA-4 structure and expression on human T cells","volume":"151","author":"Lindsten","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib12","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0952-7915(95)80077-8","article-title":"Manipulation of costimulatory signals to enhance antitumor T-cell responses","volume":"7","author":"Allison","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2015.02.003_bib15","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2015.02.003_bib16","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2015.02.003_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"Van Elsas","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib18","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.171.11.6251","article-title":"Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques","volume":"171","author":"Keler","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib19","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib20","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2015.02.003_bib21","first-page":"21","article-title":"MDX-010 (human anti CTLA-4): A phase I trial in malignant melanoma","author":"Tchekmedyian","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib22","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patient with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.clinthera.2015.02.003_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib25","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib28","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib30","first-page":"7412","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin?Cancer Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib31","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2015.02.003_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib34","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastasis: an open-label, phase II trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib37","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2015.02.003_bib38","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"10.1016\/j.clinthera.2015.02.003_bib40","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib41","first-page":"31","article-title":"Multicenter randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib42","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up for 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib43","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ctrv.2014.06.012","article-title":"Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma","volume":"40","author":"McDermott","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2015.02.003_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clindermatol.2012.08.006","article-title":"Immunomodulatory therapy for melanoma: Ipilimumab and beyond","volume":"31","author":"Callahan","year":"2013","journal-title":"Clin in Derm"},{"key":"10.1016\/j.clinthera.2015.02.003_bib46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clinthera.2015.02.003_bib47","first-page":"5s","article-title":"The neoantigen landscape underlying clinical response to ipilimumab","volume":"32","author":"Charen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib48","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.3004","article-title":"Germline genetic determinants of immunotherapy response in metastatic melanoma","volume":"32","author":"Adaniel","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib49","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.lba9008","article-title":"Ipilimumab versus placebo after complete resection of stage II melanoma: initial efficacy and safety results from EORTC 18071 phase III trial","volume":"32","author":"Eggermont","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib52","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clinthera.2015.02.003_bib53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinthera.2015.02.003_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab pulse ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.02.003_bib55","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.lba9003","article-title":"Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)","volume":"32","author":"Sznol","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T17:13:44Z","timestamp":1717780424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0149291815000697"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.02.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}